The Lysosomal Storage Disorders Support Society appeals to Prime Minister Narendra Modi for urgent funding to support patients facing treatment interruptions due to exhausted financial assistance under the National Policy for Rare Diseases. The letter emphasizes the necessity for a ... The Lysosomal Storage Disorders Support Society appeals to Prime Minister Narendra Modi for urgent funding to support patients facing treatment interruptions due to exhausted financial assistance under the National Policy for Rare Diseases. The letter emphasizes the necessity for a continuity-of-treatment mechanism to aid those suffering from life-threatening conditions, particularly children with ultra-rare diseases. It said 164 patients had exhausted the financial assistance available under NPRD, 2021, of whom around 115 were patients suffering from ultra-rare LSDs, including Gaucher and Pompe disease. ... Many of these patients are children as young as two, three, four or five years of age, it added. LSDSS appealed to urgently reinstate treatment for all clinically eligible patients and to establish an interim funding arrangement until the matter is sub judice before the Supreme Court. It added that a continuity-of-treatment mechanism must be established under NPRD to fill a structural gap in the implementation of the policy. LSDSS said, “A mechanism is urgently required so that a patient requiring lifelong or long-term therapy is not abruptly rendered ineligible merely because the prescribed financial ceiling has been reached.” · It also urged that children and patients at high clinical risk must be prioritised for treatment and that all concerned Centres of Excellence must be directed to identify and report such patients immediately. LSDSS said patients with progressive, potentially life-threatening conditions were facing treatment interruptions after exhausting their sanctioned financial assistance.

Original title: “Patients with Rare Diseases Urge Prime Minister Modi for Additional Treatment Funding, ETHealthworld”

decoding the rare integrative genomics predictive algorithms and lipidomics as a guide for in lysosomal storage disorder research

Original title: “Decoding the Rare: Integrative Genomics, Predictive Algorithms and Lipidomics as a Guide for in Lysosomal Storage Disorder Research.”

In this Q&A, Minsu Kang, vice president ... experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative ... In this Q&A, Minsu Kang, vice president of clinical development and regulatory affairs at Polaryx Therapeutics, shares his insights from his firsthand experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative diseases. Polaryx, a publicly-traded, clinical-stage biotech is developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSD). Recent funding will allow the initiation of its Phase II SOTERIA trial, evaluating its lead compound across multiple LSD indications. Minsu Kang of Polaryx Therapeutics explains how to align with regulators on study design and maintain scientific rigor Many factors go into achieving alignment with the FDA on this topic, such as off-label uses of existing medications, disease severity, and availability of natural history data that may serve as an external control arm. Having a good scientific foundation and supporting data, beyond simply referring to the unmet medical needs, can be helpful in achieving regulatory alignment. BX: In your experience, has this alignment caused any friction with the clinical development plans or maybe trial amendments?

Original title: “Navigating FDA talks in rare disease programs”

In this Q&A, Minsu Kang, vice president ... experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative ... In this Q&A, Minsu Kang, vice president of clinical development and regulatory affairs at Polaryx Therapeutics, shares his insights from his firsthand experience engaging with the FDA in the context of rare disease therapies. Kang has over 10 years in CNS development, and extensive experience working on late-stage clinical trials and regulatory affairs for a number of neurodegenerative diseases. Polaryx, a publicly-traded, clinical-stage biotech is developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSD). Recent funding will allow the initiation of its Phase II SOTERIA trial, evaluating its lead compound across multiple LSD indications. Minsu Kang of Polaryx Therapeutics explains how to align with regulators on study design and maintain scientific rigor Many factors go into achieving alignment with the FDA on this topic, such as off-label uses of existing medications, disease severity, and availability of natural history data that may serve as an external control arm. Having a good scientific foundation and supporting data, beyond simply referring to the unmet medical needs, can be helpful in achieving regulatory alignment. BX: In your experience, has this alignment caused any friction with the clinical development plans or maybe trial amendments?

Original title: “Navigating FDA talks in rare disease programs”

Real-world data are becoming increasingly important in rare disease development, particularly where small trials cannot capture every aspect of patient experience. Yang said real-world evidence can help show how a therapy affects patients beyond a narrow clinical endpoint. “What it comes down to is the holistic approach,” he said. “Real-world data shows how a treatment ... Real-world data are becoming increasingly important in rare disease development, particularly where small trials cannot capture every aspect of patient experience. Yang said real-world evidence can help show how a therapy affects patients beyond a narrow clinical endpoint. “What it comes down to is the holistic approach,” he said. “Real-world data shows how a treatment is actually helping kids, and not just its effect on a small biomarker or certain symptoms. For companies developing therapies in pediatric lysosomal storage disorders, flexibility will be essential with newer models and approaches in rare disease trials. In conditions where patient numbers are small, disease progression is variable and treatment options remain limited, the success of a clinical program may depend as much on trial design as on the therapeutic mechanism itself. Safety, ease of administration, clinical benefit, quality of life and biomarker changes all contribute to the overall evidence package. For PLX-200, Yang pointed to the potential advantage of an oral solution that could be administered more easily than more invasive approaches used in some rare neurologic diseases. He contrasted the quality-of-life implications of a treatment taken at home with therapies that may require frequent hospital visits or invasive delivery procedures. This helps shape how the therapy’s overall value may be assessed. For pediatric rare diseases, a treatment that is safer, easier to administer and broadly applicable could have meaningful clinical and practical advantages.

Original title: “Why Rare Disease Trial Design Requires the “Right Patients at the Right Time” - Xtalks”

l nbdnj allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders lsds

Original title: “l-NBDNJ allosteric chaperone for multiple defective enzymes involved in lysosomal storage disorders (LSDs).”

caregiver reports of neurodevelopmental functions in pediatric lysosomal storage disorders a scoping review

Original title: “Caregiver Reports of Neurodevelopmental Functions in Pediatric Lysosomal Storage Disorders: A Scoping Review.”